A randomized open-label clinical trial was carried out to determine the efficacy and safety of Crizotinib (250 mg twice daily), an oral kinase inhibitor, versus standard i.v. chemotherapy (75 mg docetaxel every 3 weeks) in a cohort of patients with locally advanced or metastatic ALK-positive (anaplastic lymphoma kinase - a tyrosine kinase known to be involved in this cancer) lung cancer. The primary outcome measure was progression free survival after 24 months. Patients were recruited in multiple centres across Europe, North America and Asia based on their genotype for the alk gene.What are the main characteristics of the clinical trial phase preceding this one?

Then try StudyFetch, the AI-powered platform that can answer your questions and teach you more about it!